📢 Gate Square Exclusive: #PUBLIC Creative Contest# Is Now Live!
Join Gate Launchpool Round 297 — PublicAI (PUBLIC) and share your post on Gate Square for a chance to win from a 4,000 $PUBLIC prize pool
🎨 Event Period
Aug 18, 2025, 10:00 – Aug 22, 2025, 16:00 (UTC)
📌 How to Participate
Post original content on Gate Square related to PublicAI (PUBLIC) or the ongoing Launchpool event
Content must be at least 100 words (analysis, tutorials, creative graphics, reviews, etc.)
Add hashtag: #PUBLIC Creative Contest#
Include screenshots of your Launchpool participation (e.g., staking record, reward
$GDRX
After A 30% Surge On The $NVO News, Is The Story Just Beginning?
Novo Nordisk partners with GoodRx for $499 monthly Ozempic, Wegovy
Novo Nordisk (NVO) has entered into a collaboration with GoodRx (NASDAQ:GDRX) to supply type 2 diabetes and weight loss meds Ozempic and Wegovy for $499 a month for self-pay customers.
GoodRx has surged ~29% in early morning trading Monday.
Under the arrangement, GoodRx customers who self-pay can use their prescription savings card at more than 70,000 pharmacies across the U.S. to get either of the drugs with a prescription at the discounted price.
GoodRx said that over the last year, nearly 17M people visited its website for savings and information on GLP-1 medications, such as Ozempic and Wegovy, which both contain the active ingredient semaglutide. That's a 22% increase from the previous year.